Global Health Limited (GLH) AI Stock Analysis

• Market Cap: AU$4.53M
• Dividend Yield: N/A
• Average Volume (3M): 18.95K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.36
• Revenue Growth: -9.90%
• EPS Growth: 34.07%
• Country: AU
• Employees: 49
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): >-0.01
• Shares Outstanding: 58,794,537
• 10 Day Avg. Volume: 15,411
• 30 Day Avg. Volume: 18,951
• PEG Ratio: 0.13
• Price to Book (P/B): -1.06
• Price to Sales (P/S): 0.46
• P/FCF Ratio: -5.60
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: AU$0.07 ▼(-18.89% Downside)

Global Health Limited's stock score is primarily impacted by its poor financial performance, characterized by negative margins and financial instability. Technical indicators suggest a bearish trend, and the valuation is unattractive due to a negative P/E ratio and lack of dividends. These factors collectively result in a low overall stock score.

Positive Factors

Diversified Revenue Streams

Multiple revenue lines (pharmaceuticals, medical devices, and subscription health technology) create structural resilience versus single-product risk. Recurring subscription income and institutional partnerships provide predictable cash flow and reduce revenue volatility over the next several quarters.

Improving Free Cash Flow

A large free cash flow improvement indicates strengthening cash generation capacity, which can fund R&D, payables and capital needs without immediate external financing. Sustained FCF growth over months improves operational flexibility and lowers refinancing risk if maintained.

Commitment to R&D and Innovation

Ongoing R&D focus across biotech, diagnostics and telehealth supports a pipeline of differentiated products and services. This fosters durable competitive advantages, potential new revenue streams, and alignment with structural healthcare digitalization trends over the medium term.

Negative Factors

Negative Shareholders' Equity

Negative equity signals a weak capital base and raises solvency concerns; it can constrain access to credit, increase financing costs, and heighten dilution risk if equity is used to recapitalize. This structural weakness limits strategic options and increases refinancing vulnerability.

Persistent Operating Cash Flow Deficit

Ongoing negative operating cash flow indicates core operations are not self-funding and may rely on financing or one-time items. Even with FCF improvements, sustained operating cash deficits threaten long-term sustainability and could force dilutive raises or spending cuts.

Ongoing Unprofitability

Consistent negative EBIT and net margins reflect structural profitability issues—either pricing, cost base, or scale problems. Persistent losses impede reinvestment, limit ability to build reserves, and increase reliance on external funding absent meaningful margin recovery.

Global Health Limited Business Overview & Revenue Model

Company Description

Global Health Limited provides digital health solutions for the healthcare sector in Australia. It provides mental health software for psychologists and psychiatrists; and integrated software solutions for various areas of community health and human services, including drug and alcohol, disability, post-acute care, community care, mental health services, and community rehabilitation, as well as offers software solutions for home care and aged care, consumer engagement tools, general practice, and pharmacy. The company's products include MasterCare EMR, an Electronic Medical Record; MasterCare + that helps organizations in digitizing their services and processes; MasterCare PAS, a patient administration system; PrimaryClinic, a medical and practice management software for general practitioners and specialists that share the same patient demographic. It also provides ReferralNet to send and receive various document types; LifeCard, a personal health record; and HotHealth, a digital engagement tool. In addition, the company offers MasterCare Data Warehouse that removes the need for spreadsheets, exports, and time-consuming analysis; e-switch, a middleware software to exchange data externally, internally, and between different software systems; Patient Portal, an online portal to capture patient data digitally via an online form prior to admission; and Altitude, a cloud hosting service. Global Health Limited was founded in 1985 and is headquartered in Melbourne, Australia.

How the Company Makes Money

Global Health Limited generates revenue through multiple streams, primarily by selling pharmaceuticals and medical devices to healthcare providers, hospitals, and pharmacies. The company also offers subscription-based health technology services, including telehealth platforms and health management software, which provide ongoing revenue. Additionally, GLH partners with research institutions and governmental health organizations for collaborative projects, receiving funding and grants that contribute to its earnings. The firm's focus on innovation and strategic partnerships enhances its market presence and drives growth, enabling GLH to capitalize on emerging health trends and demands.

Global Health Limited Financial Statement Overview

Summary

Global Health Limited faces significant financial challenges, including negative net profit and EBIT margins, negative stockholders' equity, and ongoing net losses. Despite some improvements in gross profit margin and free cash flow, the overall financial position is unstable and indicates financial distress.

Income Statement

Global Health Limited has shown a slight revenue growth of 2.95% in the latest period, but the company continues to face profitability challenges with a negative net profit margin of -10.00% and a negative EBIT margin of -9.25%. The gross profit margin improved to 24.21%, indicating some efficiency in managing production costs. However, consistent net losses and negative margins highlight ongoing operational difficulties.

Balance Sheet

The balance sheet reveals a concerning financial structure with negative stockholders' equity, resulting in a negative debt-to-equity ratio. This indicates financial instability and potential solvency issues. The return on equity is positive at 23.20%, but this is due to the negative equity base rather than operational success. The equity ratio is negative, reflecting a high-risk financial position.

Cash Flow

Cash flow analysis shows improvement with a significant free cash flow growth rate of 75.81%. However, the operating cash flow remains negative, and the operating cash flow to net income ratio is -0.13, indicating cash flow challenges. The free cash flow to net income ratio is 1.0, suggesting that the company is generating cash flow equivalent to its net losses, which is a positive sign amidst financial struggles.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	8.67M	8.67M	8.12M	7.82M	6.54M	7.03M
Gross Profit	2.10M	2.10M	-689.94K	-2.18M	-664.00K	812.71K
EBITDA	-792.62K	-793.08K	-1.77M	-7.19M	-1.69M	57.05K
Net Income	-866.88K	-866.63K	-1.31M	-8.05M	-2.05M	-488.00K
Balance Sheet
Total Assets	2.84M	2.84M	3.08M	3.12M	11.03M	9.04M
Cash, Cash Equivalents and Short-Term Investments	1.38M	1.38M	2.07M	2.24M	6.38M	4.84M
Total Debt	1.46M	1.46M	1.03M	44.94K	141.83K	304.11K
Total Liabilities	6.58M	6.58M	5.98M	4.74M	4.95M	5.00M
Stockholders Equity	-3.73M	-3.73M	-2.90M	-1.62M	6.09M	4.04M
Cash Flow
Free Cash Flow	-706.63K	-706.63K	-1.15M	-4.36M	-2.08M	675.18K
Operating Cash Flow	-706.63K	-706.63K	-1.13M	-3.46M	-1.18M	1.37M
Investing Cash Flow	5.00K	5.00K	-17.48K	-902.77K	-778.93K	-428.74K
Financing Cash Flow	98.20K	-10.70K	982.56K	240.86K	3.50M	3.23M

Global Health Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.09
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:GLH, the sentiment is Negative. The current price of 0.09 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and below the 200-day MA of 0.09, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 44.72 is Neutral, neither overbought nor oversold. The STOCH value of 38.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:GLH.

Global Health Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EMD	49 Neutral	AU$46.78M	-8.29	-81.30%	―	-36.68%	79.41%
ICR	44 Neutral	AU$16.17M	-5.42	―	―	241.34%	44.19%
TD1	43 Neutral	AU$2.62M	-2.80	-29.86%	―	―	78.95%
GLH	41 Neutral	AU$4.53M	-5.17	―	―	-9.90%	34.07%
HIQ	40 Underperform	AU$9.56M	-1.03	―	―	-40.05%	-49.57%
PKY	35 Underperform	AU$7.09M	-1.43	―	―	-67.78%	37.78%

Global Health Limited Corporate Events

Global Health Seeks ASX Quotation for New Shares Issued Under Employee Incentive Scheme

Global Health Limited has applied for quotation on the ASX of 104,000 new ordinary fully paid shares issued on 16 January 2026 under an employee incentive scheme. The move modestly increases the company’s quoted share capital and reflects the ongoing use of equity-based remuneration to incentivise staff, aligning employee interests with shareholders and potentially supporting retention and performance without a major impact on overall capital structure.

The most recent analyst rating on (AU:GLH) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Global Health Limited stock, see the AU:GLH Stock Forecast page.

Global Health Corrects December Half-Year Cash Flow Figures, Citing AI Investments and One-Off Costs

Global Health Limited has issued a correction to its December 2025 quarterly cash flow disclosure, revising its reported group cash flow for the six months to December 2025 from a previously stated ($986,000) to the accurate figure of ($346,000), and clarifying that this represents an 18% increase in cash outflows compared with ($292,000) in the same period of 2024. The company attributed the higher cash outflows to one-off staff exit costs and investment in multiple AI enterprise platforms deployed across the organisation, signalling a mix of restructuring expenses and strategic technology spending that may affect short-term cash usage while aiming to strengthen longer-term operational capabilities.

The most recent analyst rating on (AU:GLH) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Global Health Limited stock, see the AU:GLH Stock Forecast page.

Global Health Limited Announces Successful 2025 AGM Resolutions

Global Health Limited announced the results of its 2025 Annual General Meeting, where all proposed resolutions were carried. The resolutions included the adoption of the remuneration report, re-election of a director, ratification of the appointment of company auditors, and approval of a 10% placement capacity under ASX Listing Rule 7.1A. These outcomes reflect strong shareholder support and may enhance the company’s operational capabilities and strategic positioning in the digital health sector.

Global Health Limited Announces Change in Company Secretary

Global Health Limited has announced a change in its company secretary position, with Ms. Eryl Baron resigning and Mr. Chris Fernandes being appointed as the new Joint Company Secretary. This change is effective immediately, with Mr. Fernandes taking responsibility for communication with the ASX regarding Listing Rules Matters. This transition is part of the company’s ongoing efforts to maintain effective governance and communication within the healthcare technology sector.

Global Health Limited’s Annual General Meeting Highlights Investment Caution

Global Health Limited held its Annual General Meeting on November 25, 2025, where Group Managing Director Mathew Cherian presented. The company emphasized that it is not offering shares and disclaimed any responsibility for the accuracy or completeness of the information provided. Stakeholders are advised to conduct their own inquiries and seek professional advice if considering acquiring shares, as the company does not guarantee future performance or investment suitability.